Who is eligible for clinical trial NCT06137274?

Participants must meet the protocol's inclusion criteria for Squamous Cell Carcinoma. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06137274 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-03-31

Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC (NCT06137274)

Phase 2 Trial of Adaptive Radiotherapy Boost for Head and Neck Squamous Cell Carcinomas

🟢 Recruiting Phase2 📋 Clinical Research Protocol Sponsor: H. Lee Moffitt Cancer Center and Research Institute

🩺 Plain-English Summary (8th-Grade Level)

The purpose of the study is to determine if it is feasible to use magnetic resonance imaging (MRI) to adjust a portion of radiation therapy for patients with head and neck squamous cell carcinoma . The technique under study will be used to personalize the study treatment based on response, keeping all treatments within standard of care guidelines.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (6 items).

Location: Moffitt Cancer Center — Tampa, Florida

Age range: 18 Years

🧪 Interventions in This Study

Intensity-modulated radiotherapy (RADIATION)
Magnetic Resonance Guidance (OTHER)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
ECOG performance status of 0, 1
Patients with histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, or unknown primary in the neck.
Patients with measurable disease, either at primary site or neck per RECIST 1.1.
For patients planned to receive chemotherapy, adequate hematologic, hepatic and renal function as outlined in protocol.
International normalized ratio of prothrombin time (INR) and prothrombin time (PT) within 28 days before randomization must be WNL for the lab. Patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history.
Negative serum pregnancy test within before starting study treatment in woman with childbearing potential.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Pregnancy or lactation
Patients who have had prior radiotherapy to the head and neck or prior systemic therapy for the index cancer.
Patients who had undergone definitive surgery for the index cancer.
Patients with distant metastatic disease
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Moffitt Cancer Center — Tampa, Florida

📞 Contact the Study Coordinator

Phone: (813) 745-5467

Email: ashley.brennaman@moffitt.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Squamous Cell Carcinoma

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). — Houston, Texas
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design — Pittsburgh, Pennsylvania
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck — Indianapolis, Indiana
Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1. — Victor, New York
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck — Baltimore, Maryland

Explore by condition: All Squamous Cell Carcinoma clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗